INVESTMENT OPPORTUNITY
Medical Need
• Neurodegenerative diseases:
• No cure or impactful treatments available
• Multibillion $ healthcare burden
Focus on ALS:
• Rapid progression to full paralysis and death
• 500.000 patients worldwide
• No impactful treatment
Technology
• Small molecule regenerative technology
• RNAi-based technology platform
• Therapeutic modulation through modulation
of a key pathway and gene-silencing for
neurodegenerative damage
• Mechanism of action/target of primary
effect characterized
• Successful pre-clinical proof of
concept (PoC)
• Synergic therapeutic approach
Investment Return
• Dynamic valuation strategy
• Probability of success based on
uniquely positive animal PoC
• Promising opportunities for short-
to mid-term return of investment
Market
• Growing prevalence of neurodegenerative
diseases in elderly population
• Orphan drug pricing structure:
• market size:
$1.1 B for ALS (ww)
$3.8 B for TBI (USA)
• Increase disease awareness and rate
of
diagnosis (ALS):
• Global ALS drugs market to grow at a
CAGR of 5.39% over 2013-2019
